After assessing data from the first 46 adults with refractory nontuberculous mycobacterial lung disease who completed the ...
Discusses Discontinuation of ICoN-1 Phase III Trial for Nebulized Clofazimine in NTM Lung Disease November 9:00 ...
A phase 3 trial evaluating a nebulized clofazimine inhalation suspension (MNKD-101) for the treatment of refractory nontuberculous mycobacterial (NTM) ...
The "Nebulizer Market Share Analysis and Size - Growth Trends and Forecast Report 2025-2033" has been added to ResearchAndMarkets.com's offering. The Global Nebulizer Market is expected to reach US$ 2 ...
Get the latest on BiomX Inc.'s Q3 2025 earnings, FDA feedback on phage therapies BX004 & BX011, clinical progress, and financial outlook.
A new review led by Associate Professor Sanjay Singhal from Dr. Ram Manohar Lohia Institute of Medical Sciences sheds light on the prevalence and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback